216 related articles for article (PubMed ID: 27148684)
21. Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis.
Li G; Rivas P; Bedolla R; Thapa D; Reddick RL; Ghosh R; Kumar AP
Cancer Prev Res (Phila); 2013 Jan; 6(1):27-39. PubMed ID: 23248098
[TBL] [Abstract][Full Text] [Related]
22. Activation of mTORC1 is essential for β-adrenergic stimulation of adipose browning.
Liu D; Bordicchia M; Zhang C; Fang H; Wei W; Li JL; Guilherme A; Guntur K; Czech MP; Collins S
J Clin Invest; 2016 May; 126(5):1704-16. PubMed ID: 27018708
[TBL] [Abstract][Full Text] [Related]
23. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
24. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
25. Distinct germline progenitor subsets defined through Tsc2-mTORC1 signaling.
Hobbs RM; La HM; Mäkelä JA; Kobayashi T; Noda T; Pandolfi PP
EMBO Rep; 2015 Apr; 16(4):467-80. PubMed ID: 25700280
[TBL] [Abstract][Full Text] [Related]
26. The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer.
Hashemi V; Masjedi A; Hazhir-Karzar B; Tanomand A; Shotorbani SS; Hojjat-Farsangi M; Ghalamfarsa G; Azizi G; Anvari E; Baradaran B; Jadidi-Niaragh F
J Cell Physiol; 2019 May; 234(5):5478-5487. PubMed ID: 30417346
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol-mediated downregulation of Rictor attenuates autophagic process and suppresses UV-induced skin carcinogenesis.
Back JH; Zhu Y; Calabro A; Queenan C; Kim AS; Arbesman J; Kim AL
Photochem Photobiol; 2012; 88(5):1165-72. PubMed ID: 22272775
[TBL] [Abstract][Full Text] [Related]
28. Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway.
Selvaraj S; Sun Y; Sukumaran P; Singh BB
Mol Carcinog; 2016 May; 55(5):818-31. PubMed ID: 25917875
[TBL] [Abstract][Full Text] [Related]
29. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance.
Ghosh J; Kobayashi M; Ramdas B; Chatterjee A; Ma P; Mali RS; Carlesso N; Liu Y; Plas DR; Chan RJ; Kapur R
J Clin Invest; 2016 Jul; 126(7):2621-5. PubMed ID: 27294524
[TBL] [Abstract][Full Text] [Related]
30. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.
Liu P; Ge M; Hu J; Li X; Che L; Sun K; Cheng L; Huang Y; Pilo MG; Cigliano A; Pes GM; Pascale RM; Brozzetti S; Vidili G; Porcu A; Cossu A; Palmieri G; Sini MC; Ribback S; Dombrowski F; Tao J; Calvisi DF; Chen L; Chen X
Hepatology; 2017 Jul; 66(1):167-181. PubMed ID: 28370287
[TBL] [Abstract][Full Text] [Related]
31. Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation.
Huck B; Duss S; Hausser A; Olayioye MA
J Biol Chem; 2014 Feb; 289(6):3138-47. PubMed ID: 24337579
[TBL] [Abstract][Full Text] [Related]
32. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion.
Chen L; Xu B; Liu L; Liu C; Luo Y; Chen X; Barzegar M; Chung J; Huang S
Oncotarget; 2015 Mar; 6(9):7136-50. PubMed ID: 25762619
[TBL] [Abstract][Full Text] [Related]
33. DDX5 Silencing Suppresses the Migration of Basal cell Carcinoma Cells by Downregulating JAK2/STAT3 Pathway.
Quan Z; Zhang BB; Yin F; Du J; Zhi YT; Xu J; Song N
Technol Cancer Res Treat; 2019; 18():1533033819892258. PubMed ID: 31870221
[TBL] [Abstract][Full Text] [Related]
34. Targeting mTOR: evaluating the therapeutic potential of resveratrol for cancer treatment.
Wu Y; Liu F
Anticancer Agents Med Chem; 2013 Sep; 13(7):1032-8. PubMed ID: 23272906
[TBL] [Abstract][Full Text] [Related]
35. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
[TBL] [Abstract][Full Text] [Related]
36. Cellular signaling of amino acids towards mTORC1 activation in impaired human leucine catabolism.
Schriever SC; Deutsch MJ; Adamski J; Roscher AA; Ensenauer R
J Nutr Biochem; 2013 May; 24(5):824-31. PubMed ID: 22898570
[TBL] [Abstract][Full Text] [Related]
37. O-GlcNAcylation promotes colorectal cancer progression by regulating protein stability and potential catcinogenic function of DDX5.
Wu N; Jiang M; Han Y; Liu H; Chu Y; Liu H; Cao J; Hou Q; Zhao Y; Xu B; Xie X
J Cell Mol Med; 2019 Feb; 23(2):1354-1362. PubMed ID: 30484950
[TBL] [Abstract][Full Text] [Related]
38. A critical role for mTORC1 in erythropoiesis and anemia.
Knight ZA; Schmidt SF; Birsoy K; Tan K; Friedman JM
Elife; 2014 Sep; 3():e01913. PubMed ID: 25201874
[TBL] [Abstract][Full Text] [Related]
39. ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation.
Parrales A; López E; Lee-Rivera I; López-Colomé AM
Cell Signal; 2013 Apr; 25(4):829-38. PubMed ID: 23291002
[TBL] [Abstract][Full Text] [Related]
40. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
Sathe A; Chalaud G; Oppolzer I; Wong KY; von Busch M; Schmid SC; Tong Z; Retz M; Gschwend JE; Schulz WA; Nawroth R
PLoS One; 2018; 13(1):e0190854. PubMed ID: 29357370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
